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Abstract:  The present study was undertaken to investigate the effect of dietary supplementation with nimesulide or
eugenol on N-nitrosodiethylamine (DEN)-initiated early hepatocarcinogenesis in F344 male rats.  Both compounds did
not alter the expression of cytochrome P450 (CYP) 2E1, the enzyme that plays a major role in the activation of DEN
to genotoxic products; however, nimesulide induced the expression of CYP1A1.  Western blot analysis revealed that
COX-1 and COX-2 protein expressions were not modulated by DEN compared with normal controls.  Furthermore, post-
initiation feeding with nimesulide or eugenol did not modulate COX-2 protein expression in normal or DEN-treated rats,
whereas eugenol significantly increased the liver prostaglandin E2 (PGE2) levels of DEN-injected animals compared with
the DEN controls.  Ultimately, nimesulide or eugenol did not modify DEN-induced hepatocarcinogenesis as evidenced
by insignificant changes in the number and size of preneoplastic placental glutathione S-transferase (GST-P) positive
liver foci compared with the DEN controls.  These results suggest that COX-2, as well as prostaglandin E2, may play
no role in the post-initiation development of DEN-induced rat hepatocarcinogenesis at an early stage.    (J  Toxicol
Pathol 2009; 22: 263–271)
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Introduction
Hepatocellular carcinoma (HCC) is the most common
primary hepatic tumor worldwide.  Over 80% of deaths due
to HCC are expected to occur in Asia (Hong Kong,
Singapore and Japan) and Africa1.  Approximately 90 to
95% of these tumors are the biologic consequences of
hepatitis B virus (HBV) and hepatitis C virus (HCV)
infections2.  However, epidemiological data indicate the
importance of environmental factors in human liver
carcinogenesis and suggest that other factors may be
operative in conferring additional risk and give strong
evidence that our environment plays a more dominant role in
cancer etiology rather than genetics3.
N-nitrosodiethylamine is a potent chemical carcinogen
known to be activated by liver microsomal P450 enzymes in
experimental animals and in humans4.  The presence of
nitroso compounds and their precursors in the human
environment together with the possibility of their
endogenous formation in the human body have led to
suggestions of their potential involvement in human
cancers5.
Non-steroidal anti-inflammatory drugs (NSAIDs) are
the principal drug treatments for inflammation, pain and
fever6.  They exert their therapeutic anti-inflammatory and
antipyretic actions by inhibition of the enzyme
cyclooxygenase (COX) and subsequent production of
prostaglandins7.  The two COX isozymes, COX-1 and COX-
2, are both rate-limiting enzymes in the production of
prostanoids, prostaglandins (PGs), thromboxanes and
prostacyclins from arachidonic acid and have only
approximately 60% homology, but their active site residues
are almost entirely preserved8.
Conventional NSAIDs inhibit both COX-1 and COX-2,
affecting the housekeeping functions of COX-1 and hence
leading to many side effects like peptic ulcers as well as
gastric bleeding.  These facts have provided a new rationale
for the use of selective COX-2 inhibitors as anti-
inflammatory agents, which have attracted a great deal of
attention as more effective and safer therapeutic and cancer
chemopreventive agents that have equivalent efficacy and
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greater gastrointestinal safety than traditional NSAIDs9,10.
Nimesulide (N-(4-nitro-2-phenoxyphenyl)-
methanesulfonamide) is a sulfonanilide class selective COX-
2 inhibitor that appears to possess much less adverse effects
on the gastrointestinal tract than non-specific NSAIDs8.
In fact, evidence of up-regulated expression of COX-2
mRNA and protein in various human and animal tumor
tissues, such as the colon, stomach, breast, head and neck,
tongue, skin, pancreas, lung and urinary bladder, and
prevention of carcinogenesis by specific COX-2 inhibitors
as well as prevention of colon carcinogenesis by double
knockout of the COX-2 gene in APC gene knockout mice
strongly support the hypothesis that COX-2 could be a
chemopreventive target molecule11.  However, there have
been only few studies that have examined the
chemopreventive effects of COX-2 inhibitors on the
liver8,12,13.
Eugenol (1-allyl-4-hydroxy-3-methoxybenzene) is a
naturally occurring phenolic compound that is used as a food
flavor and fragrance agent14.  It is found in reasonable
quantities in the essential oils of different spices, such as
Syzgium aromaticum (clove), Pimenta racemosa (bay
leaves) and Cinnamomum verum (cinnamon leaf) and has
been used as an antiseptic, antibacterial and analgesic agent
in traditional medical practices in Asia as well as in dentistry
in cavity-filling procedures15.  Eugenol has been reported to
act as an in vitro and in vivo antioxidant and to protect rat
livers against carbon tetrachloride (CCl4) intoxication16.
Furthermore, eugenol inhibits 7,12-dimethyl-
benz(a)anthracene or benzo(a)pyrene-induced skin
carcinomas and suppresses human melanoma growth
through inhibition of E2F1 transcriptional activity15.
However, it has not been systematically tested in other
common cancers.
In the present study, the chemopreventive potentials of
the selective COX-2 inhibitor nimesulide and the phenolic
antioxidant eugenol were investigated at an early stage of
DEN-induced hepatocarcinogenesis in F344 male rats.
Materials and Methods
Chemicals
N-Nitrosodiethylamine (DEN) was obtained from
Tokyo Kasei Kogyo Co., Ltd.  (Japan), nimesulide was
obtained from Cayman Chemical Company (Japan) and
eugenol was obtained from Wako Pure Chemical Industries
Ltd.  (Japan).
Animals and diets
Five-week-old male F344 rats were obtained from
Charles River Japan Inc.  (Atsugi, Japan).  They were housed
in plastic cages on wood-chip bedding in an air-conditioned,
specific pathogen-free (SPF) animal room at 22 ± 2°C and
55 ± 5% humidity with a 12 h light/dark cycle.  The animals
had free access to food (Oriental MF, Oriental Yeast, Tokyo,
Japan) and water.  Diets containing eugenol or nimesulide
were prepared once weekly by mixing these compounds with
powdered basal diet in a blender for 15 min and stored at 4°C
in the dark.  All animal experiments were performed under
protocols approved by the Institutional Animal Care and Use
Committee of Nagoya City University School of Medicine.
Experimental protocol
After an acclimatization period of one week, a total of
42 six-week- old male F344 rats were used in this study.
Thirty-three male rats were given a single intraperitoneal
injection of DEN (200 mg/Kg body weight) dissolved in
sterile isotonic saline to initiate hepatocarcinogenesis.  After
one week on a pellet diet, the DEN-injected rats were
allocated into three equally-sized groups and were fed
powder diet using stainless steel containers.  Group 1
received no treatment serving as the DEN control group,
groups 2 and 3 were administered a powder diet containing
400 ppm nimesulide8,9 or 6000 ppm eugenol17, respectively,
for one or three weeks.  The remaining nine rats,
representing a normal counterpart study, received a single
intraperitoneal injection of sterile isotonic saline and were
further subdivided into three groups (3 rats/group) as
follows; the first group remained untreated, and the animals
in the second and third groups received a powder diet
containing 400 ppm nimesulide or 6000 ppm eugenol,
respectively, for three weeks (Fig. 1).  The diets were
available ad libitum and were given to the animals by freshly
replenishing the feed trays twice weekly.  Body weight and
food consumption were recorded twice weekly.
Blood collection and tissue sampling
At the end of the experiment period (two or four
weeks), rats were anesthetized under ether, and blood was
collected from the abdominal aorta into 10 mL plastic
Fig. 1. Experimental protocol.  A total of 42 six-week-old F344 male
rats were used throughout this study.  A group of thirty-three
rats (each animal was injected with DEN) and a group of nine
rats (each rat was injected with saline) were further
subdivided each into three equally-sized groups as shown.
The rats were sequentially sacrificed two or four weeks
following DEN injection or 4 weeks following saline
injection.   : Diethylnitrosamine (DEN), 200 mg/Kg b.w.,
i.p.   : Saline, i.p.   : Nimesulide 400 ppm in diet,  :
Eugenol 6000 ppm in diet,  : Basal diet.  S: Sacrifice.Said, Ogawa, Pitchakarn et al. 265
vacuum tubes, kept on ice to clot and then centrifuged.
Serum samples were then analyzed for alanine
aminotransferase (ALT) using a commercial kit.  At autopsy,
livers were immediately excised and weighed, and the liver
to body weight ratio was calculated.  The livers were then cut
into 2-3 mm thick slices with a razor blade and fixed in 10%
phosphate-buffered formalin for immunohistochemical
examination of placental glutathione S-transferase (GST-P)
positive foci expression, as well as routine hematoxylin and
eosin staining.  Other slices from the remaining livers were
immediately frozen in liquid nitrogen and stored at –80°C
until processed.
Immunohistochemistry for measurement of GST-P foci
Liver tissues fixed in phosphate-buffered formalin were
processed into paraffin embedded sections as described
previously18.  Briefly, 3 μM thick liver sections were treated
with rabbit anti-rat GST-P antibody (MBL, Nagoya, Japan)
and then sequentially with secondary antibody and avidin-
biotin complex reaction (Vectastain ABC Elite kit, Vector
Laboratories Inc., CA, USA).  The sites of peroxidase
binding were visualized with diaminobenzidine.  Sections
were then counterstained with hematoxylin for microscopic
examination.  The number and area of GST-P positive foci
(> 0.05 mm in diameter) in the liver sections were
quantitatively measured with an Image Processor for
Analytical Pathology (IPAP-WIN, Sumika Technos Co.,
Osaka, Japan).
Preparation of liver homogenate and isolation of
microsomal proteins
Frozen rat liver slices were washed with ice-cold saline
to remove excess blood.  A small piece of liver was cut on
dry ice and then homogenized in 1 mL RIPA buffer [150
mM NaCl, 1.0% Nonidet P-40, 0.5% sodium deoxycholate,
50 mM Tris-HCl (pH 8.0), 0.1% sodium dodecyl sulphate
and a cocktail of protease inhibitors] on ice for 30 s using a
Physcotron homogenizer (Tokyo, Japan).  The homogenate
was then sonicated on ice at a 20 s interval for a total of 5 min
using an ultrasonic cell disruptor.  The sonicates were
centrifuged at 15,000 g for 15 min at 4°C, and the resultant
supernatants were stored at –80°C for western blot analysis.
Hepatic microsomes were prepared by differential
centrifugation19.  Briefly, a piece of liver (approximately 50
mg) was homogenized on ice in 0.5 mL 0.25 M sucrose for
30 s.  The liver homogenate was centrifuged at 600 g for 5
min to remove unbroken cells and nuclear debris.  The
supernatant was then transferred to a 1.5 mL eppendorf tube
and centrifuged in a microfuge at 13,000 g for 15 min, and
the pellet was then discarded.  Using a Beckman TL-TB-
023B ultracentrifuge with an MLS-50 Rotor (Beckman
CoulterTM, CA, USA), the resulting supernatant was
centrifuged for one hour at 105,000 g to yield a fraction rich
in smooth endoplasmic reticula (microsomes).  All
procedures were performed at 4°C.  The 105,000 g pellet
was resuspended in 200 μL RIPA buffer and stored at –80°C
for further analysis of cytochrome P450 1A1/1A2 and 2E1
proteins by western blot.  Protein concentrations were
determined for each fraction by the method of Bradford20
using a Quick StartTM Bradford Protein Assay kit (Bio-Rad,
Hercules, CA, USA) with bovine gamma globulin as a
standard.
Western blot analysis
Supernatant samples containing 1–5 μg protein were
mixed 1:1 with Laemmli Sample buffer (Bio-Rad, Hercules,
CA, USA), which contained 62.5 mM Tris-HCl, pH 6.8,
25% glycerol, 2% SDS and 0.01% bromophenol blue, and
5% β-mercaptoethanol (Wako Pure Chemical Industries,
Osaka, Japan).  Samples were boiled for 5 min and separated
by SDS-PAGE using Bio-Rad Minigel apparatus (Bio-Rad
Laboratories, Hercules, CA, USA).  Resolving gels were
composed of 12%, 10% and 8% polyacrylamide for
separation of cytochromes, PCNA and β-actin and COX-1
and COX-2, respectively, whereas the stacking gel was
composed of 5% polyacrylamide, and both gels contained
0.1% SDS.  Protein migration was assessed using protein
standards (Kaleidoscope, Bio-Rad).  Protein bands were
electroblotted onto a nitrocellulose membrane (Hybond ECL
membrane, Amersham Pharmacia Biotech, UK) using a Bio-
Rad Trans-Blot electrophoretic transfer system.  The
membranes were blocked for one hour at room temperature
with 5% non-fat dried milk in Tris buffered saline (TBS, pH
8.0) containing 0.1% Tween-20, followed by brief washing
twice with TBS-T buffer (pH 7.5) containing 0.1 M Tris,
0.9% NaCl and 0.1% Tween-20.  The membranes were then
incubated overnight at 4°C with primary antibodies to
cytochrome P450 1A1/1A2 (goat anti-rat CYP1A1, Daichi
Pure Chemicals Co., Ltd., Japan) at 1:500 dilution in TBS-T
buffer (pH 7.5), cytochrome P450 2E1 (rabbit anti-rat
Cytochrome P450 IIE1, ECL Western Blotting kit,
Amersham Life Science, Buckinghamshire, UK) at 1:200
dilution, cyclooxygenase 1 (rabbit anti-murine COX-1
polyclonal antibody, Cayman Chemical, Ann Arbor, MI,
USA) at 1:250 dilution, cyclooxygenase 2 (rabbit anti-rat
COX-2, IBL Co., Ltd., Takasaki, Gunma, Japan) at 1:50
dilution, proliferating cell nuclear antigen (mouse anti-rat
PCNA monoclonal antibody, Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA) at 1:200 dilution and β-actin
(monoclonal anti-β-actin mouse IgG2a isotype, A 5316,
Sigma, St Louis, MO, USA) at 1:5000 dilution.  Following
incubation with primary antibody, the membranes were
washed three times in TBS-T buffer and incubated for one
hour with horseradish peroxidase-linked donkey anti-rabbit
IgG, sheep anti-mouse IgG (ECLTM, Amersham Pharmacia
Biotech, Buckinghamshire, UK) or donkey anti-goat IgG
(Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA)
secondary antibodies.  The membranes were washed three
times in TBS-T buffer, and protein signals were enhanced by
chemiluminescence (ECL Plus Western Blotting Detection
Reagents, Amersham, Buckinghamshire, UK); bands were
detected on radiographic film (Amersham HyperfilmTM
ECL, GE Healthcare Limited, Buckinghamshire, UK).266 COX-2 and PGE2 Are Not Involved in Early Rat Hepatocarcinogenesis
Measurement of PGE2
A small piece of liver (approximately 50–100 mg) was
homogenized in 0.5 mL RIPA buffer (without protease
inhibitors) on ice for 30 s using a Physcotron homogenizer
(Tokyo, Japan), the homogenate was centrifuged at 15,000 g
for 15 min at 4°C and the resultant supernatants were stored
at –80°C until use.  Tissue PGE2 was measured using an
ELISA kit provided by R&D Systems (Minneapolis, MN,
USA).  Protein concentrations were determined in
supernatants by the method of Bradford20 using a Quick
StartTM Bradford Protein Assay kit (Bio-Rad, Hercules, CA,
USA) with bovine gamma globulin as a standard.  PGE2
levels were expressed as pg/mg protein21.
Statistical analysis
The significance of differences in the means of body,
absolute and relative liver weights and serum ALT activity
between the controls and treated groups was examined by
ANOVA followed by Dunnett’s test.  In regard to the
quantitative data for liver GST-P positive foci and the PGE2
concentration, the Kruskal-Wallis test was applied followed
by the Mann-Whitney U test.  For western blot data, bands
were scanned, and densitometry measurement of the scanned
bands was performed.  Data were normalized to β-actin and
expressed as means ± SE.  The significance of differences
between the treated groups and DEN controls was examined
by ANOVA followed by the LSD test.  P<0.05 was
considered statistically significant for all tests.
Results
Body and organ weights, food intake and serum ALT
activity
Experimental details are summarized in Table 1.
Mortality during the experimental period was limited to one
rat in the nimesulide-treated DEN-injected group, which
died accidentally 3 days after the start of nimesulide
administration.  There was no significant change in the body
weights of the saline- or DEN-injected rats treated with
nimesulide or eugenol for three weeks, whereas the relative
liver weights showed a slight significant increase, with
respect to their counterpart controls.  Despite the
significantly increased liver weights, no explanation for such
increase was found on histological analysis.  Furthermore,
expression of proliferating cell nuclear antigen (PCNA; a
marker of cell proliferation), as determined by western blot,
was unchanged (data not shown), and liver toxicity of the
drugs was excluded by the insignificant change in serum
ALT activity.
Western blot analysis and PGE2 results
Western blot analysis revealed that oral administration
of nimesulide or eugenol to the DEN-injected rats did not
alter the CYP2E1 and 1A2 expressions, whereas nimesulide,
but not eugenol, significantly induced CYP1A1 expression,
as compared with the DEN controls (Fig. 2).
Cyclooxygenases 1 and 2 (COX-1 and COX-2) were found
to be expressed in normal control livers, and their expression
was not modulated following DEN exposure and/or
nimesulide or eugenol treatments (Figs. 3 and 4).  Treatment
of saline- or DEN-injected rats with nimesulide was found to
insignificantly change the liver prostaglandin E2 (PGE2)
level (Table 2).  On the other hand, eugenol administration
for 3 weeks in the DEN-injected rats produced a sharp
significant increase in liver PGE2 level (75%), as compared
with the DEN controls.
Histopathological findings and assessment of GST-P
positive foci
An assay system was established22 in which the
carcinogenic potential of chemicals can be detected by
measurement of altered liver foci as an end-point marker
Table 1. Body and Liver Weights, Alanine Aminotransferase (ALT) Activity and Intake Data of DEN- and Saline-injected Rats Treated with
Nimesulide (NIM) or Eugenol (EUG)
Groups Weeks after Body weight Liver weight ALT Average intake
DEN (g) Absolute Relative (U/L) Food Chemical
or saline (g) (%) (g/rat/day) Nimesulide Eugenol
injection (mg/rat/day) (mg/rat/day)
DEN – 2 (4) 145.75 ± 10.12 5.94 ± 0.26 4.08 ± 0.12 45.25 ± 13.30 14.42 – –
NIM 2 (4) 144.68 ± 8.39 6.56 ± 0.19* 4.54 ± 0.24* 37 ± 2.83 13.06 5.22 –
EUG 2 (4) 143.33 ± 7.33 5.95 ± 0.08 4.16 ± 0.21 40 ± 1.63 13.20 – 79.20
DEN – 4 (7) 204.94 ± 4.48 7.57 ± 0.41 3.69 ± 0.14 36.60 ± 2.19 (5) 14.17 – –
NIM 4 (6) 208.70 ± 9.23 8.29 ± 0.36 # 3.98 ± 0.10 # 35.20 ± 5.50 (5) 13.99 5.60 –
EUG 4 (7) 205.76 ± 6.60 8.20 ± 0.38 # 3.98 ± 0.09 # 42 ± 7.00 (5) 13.57 – 81.42
Saline – 4 (3) 223.07 ± 10.80 7.99 ± 0.31 3.58 ± 0.04 42.67 ± 0.58 13.82 – –
NIM 4 (3) 224.40 ± 9.88 9.09 ± 0.30‡ 4.05 ± 0.05‡ 37.67 ± 0.58 13.99 5.60 –
EUG 4 (3) 210.77 ± 14.72 8.17 ± 0.61 3.88 ± 0.02‡ 42 ± 2.65 13.32 – 79.92
Values are means ± SD.  The number of rats is given in parentheses.  *, # Significantly different from counterpart DEN controls.  ‡Significantly
different from normal controls. P<0.05 was considered significant (Dunnett’s test).Said, Ogawa, Pitchakarn et al. 267
within a relatively short period.  The preneoplastic nature of
altered hepatic foci and usefulness of such lesions as early
indicators of hepatocarcinogenicity are now well accepted,
and the validity of foci in assays for detection of
carcinogenic agents has been emphasized.  Their phenotypic
characteristics have been extensively studied using enzyme
histochemical and immunohistochemical approaches, and
the glutathione S-transferase placental form (GST-P) has
been found to be an optimal marker for clear visualization of
even very small lesions23, 24.
Two weeks after DEN injection, hematoxylin and eosin
staining of F344 rat livers showed periportal foci containing
hepatocytes with large clear cytoplasmic vacuoles and
prominent nucleoli.  These foci clearly regressed after 4
weeks.  No histopathologic changes were observed
regarding the size of hepatic foci after treatment of DEN-
injected rats with nimesulide or eugenol for one or three
weeks, as compared with the age-matching DEN controls
(Fig. 5).  Assessment of GST-P positive liver foci showed
that nimesulide or eugenol treatment did not exert any
suppressive or promotional effect on DEN-induced
hepatocarcinogenesis in rats, compared with the DEN
controls, as evidenced by the insignificant change in the
number and area of GST-P positive preneoplastic liver foci
(Figs. 6 and 7).
Discussion
The present study demonstrated that dietary
supplementation with nimesulide or eugenol did not alter the
formation of GST-P positive foci at an early stage of
nitrosodiethylamine-induced hepatocarcinogenesis in F344
male rats.
It is well documented that cytochrome P450 2E1
enzyme plays a major role in the activation of
nitrosodiethylamine (DEN) into genotoxic products;
moreover, other cytochromes like 1A2, 2B1, 2D1 and 1A1
are also involved4.  To the best of our knowledge, the
literature implies no evidence regarding the effect of
nimesulide on phase I enzymes, whereas eugenol appears to
act as a better inducer of phase II rather than phase I
enzymes16.  On the basis of the present findings, nimesulide,
but not eugenol, was reported herein for the first time to
induce cytochrome P450 1A1 expression.  In spite of the
increased expression of CYP1A1 by nimesulide, CYP2E1
expression was not modulated by either eugenol or
nimesulide, and as a consequence, the formation of enzyme-
altered placental glutathione S-transferase (GST-P)
preneoplastic foci, an end-point marker for
hepatocarcinogenesis, was unchanged.
Fig. 2. A representative western blot showing the expression of
cytochrome P450 (CYP) 1A1/1A2 and 2E1 proteins in the
livers of F344 male rats two weeks after DEN injection and
treatment with nimesulide (NIM) or eugenol (EUG).  The
histogram shows the relative densities of bands normalized to
β-actin (means ± SE).  * Significantly different from the DEN
controls at P<0.05 by LSD test.
Table 2. Statistical Significance of the Liver Prostaglandin E2
(PGE2) Concentration of DEN- and Saline-injected Rats
Treated with Nimesulide (NIM) or Eugenol (EUG)
Groups Weeks after DEN or PGE2 concentration
saline injection (pg/mg protein)
DEN – 2 (3) 687.67 ± 249.52
NIM 2 (3) 661.63 ± 170.31
EUG 2 (3) 865.43 ± 64
DEN – 4 (5) 492.78 ± 57.01
NIM 4 (5) 471.42 ± 53.85
EUG 4 (5) 864.54 ± 64.76 *
Saline – 4 (3) 726.80 ± 96.12
NIM 4 (3) 523.77 ± 123.27
EUG 4 (3) 606.27 ± 179.49
Values are means ± SE.  The number of rats is given in parentheses.
* P<0.05 was considered significant (Mann-Whitney U test)
compared with the counterpart DEN controls.268 COX-2 and PGE2 Are Not Involved in Early Rat Hepatocarcinogenesis
It has been reported that COX-2 protein expression was
upregulated following daily administration of N-
nitrosodiethylamine in drinking water (0.01%) for 15 weeks
to male Wistar rats during hepatocellular carcinoma
induction, as compared with normal controls5.  In contrast,
our data revealed that COX-2 expression was not modulated
4 weeks post injection of rats with a single dose of DEN
compared with normal controls.  It is well known that
administration of a single i.p. dose of DEN (200 mg/Kg body
weight) to rats is carcinogenic but only after a year or
more25; it is therefore possible that COX-2 plays no role in
the post-initiation development of DEN-induced rat
hepatocarcinogenesis at an early stage (4 weeks).
Nimesulide administration for 12 weeks at doses 200-
800 ppm in diet has been reported to significantly reduce the
number and size of enzyme-altered preneoplastic GST-P
positive liver foci during hepato- carcinogenesis induced by
a choline-deficient, L-amino acid-defined diet in F344 male
rats, and direct evidence of the involvement of COX-2 in the
early stage of hepatocarcinogenesis associated with fatty
change, fibrosis and cirrhosis has been provided8.  In
contrast, another study13 demonstrated that oral
administration of nimesulide (10 ppm in diet for 6 weeks) to
DEN-injected F344 male rats in a medium-term liver
carcinogenesis bioassay did not induce any significant
reduction in GST-P positive liver foci, as compared with
DEN controls; however, the authors attributed this lack of
effect to a low nimesulide dose that was unable to induce any
chemopreventive potential.  According to our results, an
average daily intake of 400 ppm nimesulide corresponds to
28 mg/Kg body weight, which is approximately 8 times the
respective maximum tolerated dose in humans that is 200 mg
per person per day9,11.  Even though a high dose was given to
the rats in the present study, nimesulide did not significantly
modulate COX-2 protein expression or PGE2 levels,
suggesting that a three week period of nimesulide
administration was insufficient to alter both parameters and
that chronic administration of COX inhibitors is needed in
long-term carcinogenesis study.
Several lines of evidence show that the anti-
inflammatory and anticarcinogenic actions of eugenol
compounds depend on inhibition of COX-2 expression26,27.
Expression of COX-2 is stimulated by nitric oxide through
the c-AMP response element.  Eugenol has been reported to
reduce nitric oxide (NO) production in lipopolysaccharide-
treated macrophages by inhibiting the expression of
inducible nitric oxide synthase (iNOS) protein and further
decreases the expression of COX-2 protein28.  In the present
study, a significant sharp increase in the liver PGE2 level,
which reached 75.4%, was recorded following oral
Fig. 3. A representative western blot showing the expression of
cyclooxygenase (COX)-1 and COX-2 proteins in the livers of
F344 male rats four weeks following DEN injection and
treatment with nimesulide (NIM) or eugenol (EUG).  The
histogram shows the relative densities of bands normalized to
β-actin (means ± SE).
Fig. 4. A representative western blot showing the expression of
COX-1 and COX-2 proteins in the livers of normal F344
males, livers of those treated with nimesulide or eugenol and
livers of DEN-injected rats.  The histogram shows the relative
densities of bands normalized to β-actin (means ± SE).Said, Ogawa, Pitchakarn et al. 269
Fig. 6. Statistical comparison of the number of GST-P positive liver
cell foci (No./cm2) in F344 male rats two and four weeks after
DEN injection and treatment with nimesulide (NIM) or
eugenol (EUG), as compared with their counterpart DEN
controls (values are means ± SE).
Fig. 7. Statistical comparison of the areas of GST-P positive liver
cell foci (mm2/cm2) in F344 male rats two and four weeks
following DEN injection and treatment with nimesulide
(NIM) or eugenol (EUG), as compared with their counterpart
DEN controls (values are means ± SE).
Fig. 5. Representative hematoxylin and eosin staining (A, C, E, G, I and K) and immunohistochemical findings of GST-P
positive liver preneoplastic foci (B, D, F, H, J and L) of the DEN controls two weeks (A and B) and four weeks (C
and D) after DEN injection (200 mg/Kg b.w.) and following treatment with nimesulide (E and F, G and H) or
eugenol ( I and J, K and L) for one or three weeks , respectively (×20).  Arrows indicate foci.270 COX-2 and PGE2 Are Not Involved in Early Rat Hepatocarcinogenesis
administration of DEN-injected rats with eugenol for three
weeks, as compared with the DEN controls, even though
administration of eugenol per os to normal rats did not
significantly alter the liver PGE2 level, as compared with
normal rats.  We therefore suggest that 1) eugenol induced
COX-1 or COX-2 enzyme activities without modifying their
protein expression, causing a differential contribution of
COXs to the PGE2 level to occur in the DEN-injected
animals, or 2) reactive intermediates may have been formed
during microsomal metabolism of eugenol following DEN
exposure, which may have induced the activity of
prostaglandin E synthase, or may have even altered the
activity of the liver prostaglandin dehydrogenase and
cytochrome P450 monooxygenases involved in PGE2
inactivation.  However, the effect of eugenol on PGE2
metabolism remains to be elucidated.
In conclusion, the present study clearly demonstrates
that the early carcinogenic response of DEN in the rat liver
remains unchanged in the presence of nimesulide, a selective
COX-2 inhibitor, and the phenolic antioxidant eugenol.  This
lack of modification is partly interpreted as a result of the
inability of both compounds to modulate CYP2E1
expression.  Furthermore, the COXs and PGE2 are not
involved in the early stage of DEN-induced
hepatocarcinogenesis in the present model.
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